Circulating Microbial Metabolites Predict Tumor Relapse and Chemotherapy Efficacy in Nasopharyngeal Carcinoma

Abstract

The value of microbial metabolites in prognosis and treatment response prediction in patients with nasopharyngeal carcinoma (NPC) remains unclear. Here, through the untargeted metabolomic analysis of plasma in 48 paired NPC patients with or without tumor relapse, we identified distinct circulating metabolite atlases between NPC patients with different prognoses. We used bootstrap least absolute shrinkage and selection operator (LASSO) on a penalized Cox regression model to select metabolites and constructed a metabolite risk model comprising four microbial metabolites in a training cohort (n = 202), and validated it in an independent test cohort (n = 201) and an external validation cohort (n = 180). The model stratified patients into three risk groups. Patients in the low-risk group had optimal DFS, DMFS, and OS, compared with those in the intermediate-risk group. High-risk patients had poor survival across all clinical endpoints. Furthermore, patients in the intermediate-risk group could benefit from induction chemotherapy. In addition, we generated a nomogram integrating the risk model, N stage, and plasma EBV-DNA load, which further enhanced the predictive accuracy of the metabolite risk model. Collectively, we developed and validated a robust predictive model based on serum metabolites, promoting risk stratification and enhancing treatment outcomes in patients with NPC. We identified distinct circulating metabolite atlases between NPC patients with different prognoses in the training cohort (n = 202). A risk model, comprising four microbial metabolites, was developed to stratify patients into three risk groups. Patients in the low-risk group had optimal DFS, DMFS, and OS, compared with those in the intermediate-risk group. High-risk patients had poor survival across all clinical endpoints. Findings were validated using an independent test cohort (n = 201) and an external validation cohort (n = 180). Specifically, a nomogram integrating the risk model, N stage, and plasma EBV-DNA load enhanced predictive accuracy. Moreover, patients benefited from induction chemotherapy with improved survival in the intermediate-risk group, but not in the low-risk and high-risk groups.

Keywords

circulating biomarker / metabolite / microbiota / nasopharyngeal carcinoma

References

[1] Y. P. Chen, A. T. C. Chan, Q. T. Le, P. Blanchard, Y. Sun, and J. Ma, “Nasopharyngeal Carcinoma,” Lancet 394, no. 10192 (2019): 64–80.

[2] Y. Zhang, L. Chen, G. Q. Hu, et al., “Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma,” New England Journal of Medicine 381, no. 12 (2019): 1124–1135.

[3] Y. Sun, W. F. Li, N. Y. Chen, et al., “Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial,” Lancet Oncology 17, no. 11 (2016): 1509–1520.

[4] E. P. Hui, B. B. Ma, S. F. Leung, et al., “Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27, no. 2 (2009): 242–249.

[5] X. J. Du, G. Y. Wang, X. D. Zhu, et al., “Refining the 8th Edition TNM Classification for EBV Related Nasopharyngeal Carcinoma,” Cancer Cell 42, no. 3 (2024): 464–473.e463.

[6] J. Lv, Y. Chen, G. Zhou, et al., “Liquid Biopsy Tracking During Sequential Chemo-Radiotherapy Identifies Distinct Prognostic Phenotypes in Nasopharyngeal Carcinoma,” Nature Communications 10, no. 1 (2019): 3941.

[7] N. Liu, N. Y. Chen, R. X. Cui, et al., “Prognostic Value of a microRNA Signature in Nasopharyngeal Carcinoma: A microRNA Expression Analysis,” Lancet Oncology 13, no. 6 (2012): 633–641.

[8] X. R. Tang, Y. Q. Li, S. B. Liang, et al., “Development and Validation of a Gene Expression-Based Signature to Predict Distant Metastasis in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective, Multicentre, Cohort Study,” Lancet Oncology 19, no. 3 (2018): 382–393.

[9] Y. L. Liang, Y. Zhang, X. R. Tan, et al., “A lncRNA Signature Associated With Tumor Immune Heterogeneity Predicts Distant Metastasis in Locoregionally Advanced Nasopharyngeal Carcinoma,” Nature Communications 13, no. 1 (2022): 2996.

[10] M. Ignatiadis, G. W. Sledge, and S. S. Jeffrey, “Liquid Biopsy Enters the Clinic—Implementation Issues and Future Challenges,” Nature Reviews Clinical Oncology 18, no. 5 (2021): 297–312.

[11] L. Q. Tang, C. F. Li, J. Li, et al., “Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma,” Journal of the National Cancer Institute 108, no. 1 (2016): djv291.

[12] J. Y. Li, C. L. Huang, W. J. Luo, et al., “An Integrated Model of the Gross Tumor Volume of Cervical Lymph Nodes and Pretreatment Plasma Epstein-Barr Virus DNA Predicts Survival of Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era: A Big-Data Intelligence Platform-Based Analysis,” Therapeutic Advances in Medical Oncology 11 (2019): 1758835919877729.

[13] J. Lv, L. X. Xu, Z. X. Li, et al., “Longitudinal On-Treatment Circulating Tumor DNA as a Biomarker for Real-Time Dynamic Risk Monitoring in Cancer Patients: The EP-SEASON Study,” Cancer Cell 42, no. 8 (2024): 1401–1414.e1404.

[14] W. Z. Li, H. J. Wu, S. H. Lv, et al., “Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma,” JAMA Network Open 4, no. 9 (2021): e2124721.

[15] K. Y. Kim, Q. T. Le, S. S. Yom, et al., “Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer,” Journal of the National Cancer Institute 109, no. 4 (2017): djx007.

[16] R. Tan, S. K. A. Phua, Y. L. Soong, et al., “Clinical Utility of Epstein-Barr Virus DNA and Other Liquid Biopsy Markers in Nasopharyngeal Carcinoma,” Cancer Communications 40, no. 11 (2020): 564–585.

[17] B. Chen, D. Wang, J. Huang, et al., “A Seven-Gene 5-Hydroxymethylcytosine Signature in Circulating Cell-Free DNA for Prognostic Stratification of Nasopharyngeal Carcinoma,” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 216 (2026): 111366.

[18] A. Reffai, M. Hori, R. Adusumilli, et al., “Integrated Plasma and Tumor Proteomics of Nasopharyngeal Carcinoma in a Moroccan Cohort,” International Journal of Molecular Sciences 26, no. 12 (2025): 5771.

[19] H. Xie, L. Zhang, L. Chen, et al., “Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma,” ImmunoTargets and Therapy 14 (2025): 577–587.

[20] Y. Liang, J. Li, Q. Li, et al., “Plasma Protein-Based Signature Predicts Distant Metastasis and Induction Chemotherapy Benefit in Nasopharyngeal Carcinoma,” Theranostics 10, no. 21 (2020): 9767–9778.

[21] W. Z. Li, X. Hua, S. H. Lv, et al., “A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma,” Journal of Inflammation Research 14 (2021): 817–828.

[22] S. H. Lv, W. Z. Li, H. Liang, G. Y. Liu, W. X. Xia, and Y. Q. Xiang, “Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy,” Journal of Inflammation Research 14 (2021): 2225–2237.

[23] D. R. Schmidt, R. Patel, D. G. Kirsch, C. A. Lewis, M. G. Vander Heiden, and J. W. Locasale, “Metabolomics in Cancer Research and Emerging Applications in Clinical Oncology,” CA: A Cancer Journal for Clinicians 71, no. 4 (2021): 333–358.

[24] M. K. Karjalainen, S. Karthikeyan, C. Oliver-Williams, et al., “Genome-Wide Characterization of Circulating Metabolic Biomarkers,” Nature 628, no. 8006 (2024): 130–138.

[25] Y. Xiao, D. Ma, Y. S. Yang, et al., “Comprehensive Metabolomics Expands Precision Medicine for Triple-Negative Breast Cancer,” Cell Research 32, no. 5 (2022): 477–490.

[26] W. R. Wikoff, A. T. Anfora, J. Liu, et al., “Metabolomics Analysis Reveals Large Effects of Gut Microflora on Mammalian Blood Metabolites,” Proceedings of the National Academy of Sciences of the United States of America 106, no. 10 (2009): 3698–3703.

[27] B. Roje, B. Zhang, E. Mastrorilli, et al., “Gut Microbiota Carcinogen Metabolism Causes Distal Tissue Tumours,” Nature 632, no. 8027 (2024): 1137–1144.

[28] Q. Yang, B. Wang, Q. Zheng, et al., “A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy,” Advanced Science 10, no. 15 (2023): e2207366.

[29] R. Gao, C. Wu, Y. Zhu, et al., “Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites,” Gastroenterology 163, no. 4 (2022): 1024–1037.e1029.

[30] F. Chen, X. Dai, C. C. Zhou, et al., “Integrated Analysis of the Faecal Metagenome and Serum Metabolome Reveals the Role of Gut Microbiome-Associated Metabolites in the Detection of Colorectal Cancer and Adenoma,” Gut 71, no. 7 (2022): 1315–1325.

[31] J. Liu, W. Geng, H. Sun, et al., “Integrative Metabolomic Characterisation Identifies Altered Portal Vein Serum Metabolome Contributing to Human Hepatocellular Carcinoma,” Gut 71, no. 6 (2022): 1203–1213.

[32] Y. Sun, X. Zhang, D. Hang, et al., “Integrative Plasma and Fecal Metabolomics Identify Functional Metabolites in Adenoma-Colorectal Cancer Progression and as Early Diagnostic Biomarkers,” Cancer Cell 42, no. 8 (2024): 1386–1400.e1388.

[33] S. Han, W. Van Treuren, C. R. Fischer, et al., “A Metabolomics Pipeline for the Mechanistic Interrogation of the Gut Microbiome,” Nature 595, no. 7867 (2021): 415–420.

[34] T. Wilmanski, C. Diener, N. Rappaport, et al., “Gut Microbiome Pattern Reflects Healthy Ageing and Predicts Survival in Humans,” Nature Metabolism 3, no. 2 (2021): 274–286.

[35] H. Qiao, X. R. Tan, H. Li, et al., “Association of Intratumoral Microbiota With Prognosis in Patients with Nasopharyngeal Carcinoma From 2 Hospitals in China,” JAMA Oncology 8, no. 9 (2022): 1301–1309.

[36] R. Guo, L. L. Tang, Y. P. Mao, et al., “Proposed Modifications and Incorporation of Plasma Epstein-Barr Virus DNA Improve the TNM Staging System for Epstein-Barr Virus-Related Nasopharyngeal Carcinoma,” Cancer 125, no. 1 (2019): 79–89.

[37] E. Kadosh, I. Snir-Alkalay, A. Venkatachalam, et al., “The Gut Microbiome Switches Mutant p53 From Tumour-suppressive to Oncogenic,” Nature 586, no. 7827 (2020): 133–138.

[38] H. N. Bell, R. J. Rebernick, J. Goyert, et al., “Reuterin in the Healthy Gut Microbiome Suppresses Colorectal Cancer Growth Through Altering Redox Balance,” Cancer Cell 40, no. 2 (2022): 185–200.e186.

[39] Y. Lei, Y. Q. Li, W. Jiang, et al., “A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma,” Journal of the National Cancer Institute 113, no. 4 (2021): 471–480.

[40] A. P. Gomes, D. Ilter, V. Low, et al., “Altered Propionate Metabolism Contributes to Tumour Progression and Aggressiveness,” Nature Metabolism 4, no. 4 (2022): 435–443.

[41] O. Olivares, J. R. Mayers, V. Gouirand, et al., “Collagen-Derived Proline Promotes Pancreatic Ductal Adenocarcinoma Cell Survival Under Nutrient-Limited Conditions,” Nature Communications 8 (2017): 16031.

[42] Z. Ding, R. E. Ericksen, N. Escande-Beillard, et al., “Metabolic Pathway Analyses Identify Proline Biosynthesis Pathway as a Promoter of Liver Tumorigenesis,” Journal of Hepatology 72, no. 4 (2020): 725–735.

[43] S. E. Pilley, M. Hennequart, A. Vandekeere, et al., “Loss of Attachment Promotes Proline Accumulation and Excretion in Cancer Cells,” Science Advances 9, no. 36 (2023): eadh2023.

[44] C. A. Reichard, B. D. Naelitz, Z. Wang, et al., “Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort,” Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 31, no. 1 (2022): 192–199.

[45] K. Lirdprapamongkol, J. P. Kramb, T. Suthiphongchai, et al., “Vanillin Suppresses Metastatic Potential of Human Cancer Cells Through PI3K Inhibition and Decreases Angiogenesis in Vivo,” Journal of Agricultural and Food Chemistry 57, no. 8 (2009): 3055–3063.

[46] J. H. Dai, X. R. Tan, H. Qiao, and N. Liu, “Emerging Clinical Relevance of Microbiome in Cancer: Promising Biomarkers and Therapeutic Targets,” Protein & Cell 15, no. 4 (2024): 239–260.

[47] C. N. Spencer, J. L. McQuade, V. Gopalakrishnan, et al., “Dietary Fiber and Probiotics Influence the Gut Microbiome and Melanoma Immunotherapy Response,” Science 374, no. 6575 (2021): 1632–1640.

[48] J. Tintelnot, Y. Xu, T. R. Lesker, et al., “Microbiota-Derived 3-IAA Influences Chemotherapy Efficacy in Pancreatic Cancer,” Nature 615, no. 7950 (2023): 168–174.

[49] X. Yuan, Q. Xu, F. Du, et al., “Development and Validation of a Model to Predict Cognitive Impairment in Traumatic Brain Injury Patients: A Prospective Observational Study,” EClinicalMedicine 80 (2025): 103023.

[50] M. van Smeden, K. G. Moons, J. A. de Groot, et al., “Sample Size for Binary Logistic Prediction Models: Beyond Events per Variable Criteria,” Statistical Methods in Medical Research 28, no. 8 (2019): 2455–2474.

[51] E. Vittinghoff and C. E. McCulloch, “Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression,” American Journal of Epidemiology 165, no. 6 (2007): 710–718.

[52] S. Bijlsma, I. Bobeldijk, E. R. Verheij, et al., “Large-Scale Human Metabolomics Studies: A Strategy for Data (pre-) Processing and Validation,” Analytical Chemistry 78, no. 2 (2006): 567–574.

[53] H. Luan, F. Ji, Y. Chen, and Z. Cai, “statTarget: A Streamlined Tool for Signal Drift Correction and Interpretations of Quantitative Mass Spectrometry-based Omics Data,” Analytica Chimica Acta 1036 (2018): 66–72.

[54] R. L. Camp, M. Dolled-Filhart, and D. L. Rimm, “X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10, no. 21 (2004): 7252–7259.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.